Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Abiraterone Acetate 2vedolizumab 1tislelizumab 1onapristone 1olaparib 1abiraterone 1Pluvicto 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Lutetium-177 1Lutetium 1LDP-02 1Infliximab 1Immunoglobulin G 1Docetaxel 1Disulfides 1CT-P13 1BAY 86-7548 1Androgen Antagonists 1Adrenal Cortex Hormones 1Administration, Intravesical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urogenital Neoplasms × Administration, Intravesical × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔